SLC16A1 and glioblastoma: The accumulation of the BCCA metabolites, branch chain keto acids (BCKAs), excreted by glioblastoma cells via monocarboxylate transporter 1 (MCT1), suppresses antitumor immune responses by attenuating the phagocytic activity of macrophages (90).